PERE ARAGONÉS, PRESIDENT OF THE GOVERNMENT OF CATALONIA, VISITS ESTEVE’S MAIN INDUSTRIAL PLANT
During his visit to the Celrà plant, Albert Esteve, Chairman of ESTEVE's Board of Directors, explained how important innovation is when it comes to improving patient health. In this regard, the company's latest major milestone has been the FDA's approval of Seglentis®, a drug for the treatment of acute pain in adults that has been entirely developed by ESTEVE's R&D team.
The President also learned about the company's sustainability strategy which is in line with the United Nations Sustainable Development Goals for 2030.
The President of the Government of Catalonia, Pere Aragonés, together with the Health Ministry, Manel Balcells, and the Delegate of the Government of Catalonia in Girona, Laia Cañigueral, today visited one of ESTEVE's production plants in Spain, specifically the one located in the town of Celrà, in Girona.
During his visit, Albert Esteve, Chairman of ESTEVE's Board of Directors, explained a number of issues of interest for the well-being of citizens, such as the importance of putting the patient at the very center of healthcare, the company's commitment to sustainability and to innovation as a means to improve people's health. "ESTEVE is an international company that was set up in Catalonia more than 100 years ago. Since then it has remained steadfast in its determination to improve people's lives, an objective that can be seen in each and everything we do and in every decision we make", Albert Esteve explained.
The importance of innovation
Innovation is essential to meet patient needs, and that is precisely how ESTEVE understands it. One of the company's most recent milestones was the approval in 2021 by the U.S. Food and Drug Administration of Seglentis®, a drug for the treatment of acute pain in adults1-2. Launched onto the U.S. market last May, Seglentis® is in fact the first drug to be developed entirely by ESTEVE's R&D team.
The patient at the very center
ESTEVE has drugs that address multiple therapeutic areas, albeit with a particular focus on oncology, the central nervous system, ophthalmology and pain. The company is also present in the international arena with a structure that makes it possible to cover unmet health needs. With this same objective in mind, the company is currently developing its global business dedicated to the manufacture of active substances for third parties. In this sense, special mention should be made of the Celrà plant, which has a total reaction volume of more than 300m³ for the scaling and manufacture of active pharmaceutical ingredients. The plant employs 250 workers.
Sustainability as a strategic pillar
Caring for people, caring for the environment and caring for the business are the three pillars that underpin ESTEVE's sustainability strategy, in line with the United Nations Sustainable Development Goals for 2030.
The aim of this strategy is to support the fight against climate change, which is considered strategic by ESTEVE and is directly related to improving people's lives.
1. British Journal of Clinical Pharmacology. 2017;83(12):2718-2728.
2. Clinical Therapeutics. 2021;43(6):1051-1065.